甲胎蛋白在肝癌的诊断和治疗中的研究进展

Research progress of AFP in the diagnosis and therapy of hepatocellular carcinoma

摘要:

肝细胞癌 (Hepatocellular carcinoma，HCC) 是致死率第3的恶性肿瘤，也是全球第5大常见癌症。肝癌在临床上的治疗手段非常有限，患者的总生存率也很低。因此，肝癌的早期诊断和治疗对于患者总生存率有着重要的影响。甲胎蛋白 (Alpha-fetoprotein，AFP) 是最早发现也是目前应用最广泛的肝癌标志物之一。目前，多项研究表明，作为一个特异性的癌基因，AFP在肝癌的发生、发展、诊断和治疗中有巨大的研究价值。文中简述了AFP在肝癌发生发展中的分子调控机制以及在肝癌细胞逃避免疫监视中的作用，着重阐述AFP作为重要的肝癌靶标分子在肝癌的临床诊断和治疗研究中的应用。

Abstract:

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths and the fifth most common cancer worldwide. Clinically therapeutic options for HCC are very limited, and the overall survival rate of patients is very low. Therefore, early diagnosis and treatment of HCC have important impact on overall survival of patients. At present, alpha-fetoprotein (AFP) is one of the most widely used serological markers for HCC. Many evidences have shown that as a specific onco-protein, AFP has great research value in the occurrence, development, diagnosis and treatment of HCC. Here, we briefly introduce the molecular mechanism of AFP in the regulation of HCC occurrence and development, and its role in tumor escape from immune surveillance. We focus on the application of AFP as an important HCC target or carcino-embryonic antigen (CEA) in HCC clinical diagnosis and treatment.